BACKGROUND: The aim of the study was to compare clinical characteristics of real-life atrial fibrillation (AF) patients with populations included in randomized clinical trials (ROCKET AF and RE-LY). METHODS: The analysis included 3528 patients who are participants of the ongoing, multicentre, retrospective CRAFT study. The study is registered in ClinicalTrials.gov: NCT02987062. The study is based on a retrospective analysis of hospital records of AF patients treated with vitamin K antagonists (VKAs) (acenocoumarol, warfarin) and non-vitamin K oral anticoagulants (NOACs) (dabigatran, rivaroxaban). CHADS2 score was used for risk of stroke stratification. RESULTS: VKA was prescribed in 1973 (56.0%), while NOAC in 1549 (44.0%), including dabigatran - 504 (14.3%) and rivaroxaban - 1051 (29.8%), of the 3528 patients. VKA patients in the CRAFT study were at significantly lower risk of stroke (CHADS2 1.9 ± 1.3), compared with the VKA population from the RE-LY (2.1 ± 1.1) and the ROCKET-AF (3.5 ± 1.0). Patients in the CRAFT study treated with NOAC (CHADS2 for patients on dabigatran 150 mg - 1.3 ± 1.2 and on rivaroxaban - 2.2 ± 1.4) had lower risk than patients from the RE-LY (2.2 ± 1.2) and the ROCKET AF (3.5 ± 0.9). CONCLUSIONS: Real-world patients had a lower risk of stroke than patients included in the RE-LY and ROCKET AF trials.
BACKGROUND: The aim of the study was to compare clinical characteristics of real-life atrial fibrillation (AF) patients with populations included in randomized clinical trials (ROCKET AF and RE-LY). METHODS: The analysis included 3528 patients who are participants of the ongoing, multicentre, retrospective CRAFT study. The study is registered in ClinicalTrials.gov: NCT02987062. The study is based on a retrospective analysis of hospital records of AFpatients treated with vitamin K antagonists (VKAs) (acenocoumarol, warfarin) and non-vitamin K oral anticoagulants (NOACs) (dabigatran, rivaroxaban). CHADS2 score was used for risk of stroke stratification. RESULTS: VKA was prescribed in 1973 (56.0%), while NOAC in 1549 (44.0%), including dabigatran - 504 (14.3%) and rivaroxaban - 1051 (29.8%), of the 3528 patients. VKA patients in the CRAFT study were at significantly lower risk of stroke (CHADS2 1.9 ± 1.3), compared with the VKA population from the RE-LY (2.1 ± 1.1) and the ROCKET-AF (3.5 ± 1.0). Patients in the CRAFT study treated with NOAC (CHADS2 for patients on dabigatran 150 mg - 1.3 ± 1.2 and on rivaroxaban - 2.2 ± 1.4) had lower risk than patients from the RE-LY (2.2 ± 1.2) and the ROCKET AF (3.5 ± 0.9). CONCLUSIONS: Real-world patients had a lower risk of stroke than patients included in the RE-LY and ROCKET AF trials.
Entities:
Keywords:
non-valvular atrial fibrillation; oral anticoagulation; randomized trial; real-world study
Authors: Cees B de Vos; Ron Pisters; Robby Nieuwlaat; Martin H Prins; Robert G Tieleman; Robert-Jan S Coelen; Antonius C van den Heijkant; Maurits A Allessie; Harry J G M Crijns Journal: J Am Coll Cardiol Date: 2010-02-23 Impact factor: 24.094
Authors: S Saturni; F Bellini; F Braido; P Paggiaro; A Sanduzzi; N Scichilone; P A Santus; L Morandi; A Papi Journal: Pulm Pharmacol Ther Date: 2014-01-24 Impact factor: 3.410
Authors: Paweł Balsam; Krzysztof Ozierański; Agata Tymińska; Katarzyna Żukowska; Martyna Zaleska; Katarzyna Szepietowska; Kacper Maciejewski; Michał Peller; Marcin Grabowski; Piotr Lodziński; Anna Praska-Ogińska; Inna Zaboyska; Łukasz Kołtowski; Anna Kowalczuk; Janusz Bednarski; Krzysztof J Filipiak; Grzegorz Opolski Journal: Kardiol Pol Date: 2018-01-19 Impact factor: 3.108
Authors: Janusz Bednarski; Paweł Balsam; Agata Tymińska; Krzysztof Ozierański; Katarzyna Żukowska; Martyna Zaleska; Katarzyna Szepietowska; Kacper Maciejewski; Michał Peller; Anna Praska-Oginska; Inna Zaboyska; Grzegorz Opolski Journal: Pol Arch Intern Med Date: 2018-03-17
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Krzysztof Ozierański; Agnieszka Kapłon-Cieślicka; Michał Peller; Agata Tymińska; Paweł Balsam; Michalina Galas; Michał Marchel; Marisa Crespo-Leiro; Aldo Pietro Maggioni; Jarosław Drożdż; Grzegorz Opolski Journal: Kardiol Pol Date: 2015-09-14 Impact factor: 3.108
Authors: Alicia DeFelipe-Mimbrera; Araceli Alonso Cánovas; Marta Guillán; Consuelo Matute; Susana Sainz de la Maza; Antonio Cruz; Rocío Vera; Jaime Masjuan Journal: Biomed Res Int Date: 2014-07-15 Impact factor: 3.411
Authors: Cezary Maciejewski; Krzysztof Ozierański; Mikołaj Basza; Piotr Lodziński; Andrzej Śliwczyński; Leszek Kraj; Maciej Janusz Krajsman; Jefte Prado Paulino; Agata Tymińska; Grzegorz Opolski; Andrzej Cacko; Marcin Grabowski; Paweł Balsam Journal: Int J Environ Res Public Health Date: 2022-09-22 Impact factor: 4.614